Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by My Legacy Advisors LLC

My Legacy Advisors LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,263 shares of the pharmaceutical company’s stock after purchasing an additional 63 shares during the quarter. My Legacy Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,085,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of VRTX. Quent Capital LLC increased its holdings in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company’s stock valued at $249,000 after buying an additional 22 shares during the last quarter. Advisor OS LLC increased its position in Vertex Pharmaceuticals by 4.4% during the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after purchasing an additional 23 shares during the period. Sculati Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 1.0% in the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock worth $1,029,000 after buying an additional 25 shares during the last quarter. Avidian Wealth Enterprises LLC boosted its stake in Vertex Pharmaceuticals by 2.1% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after purchasing an additional 25 shares in the last quarter. Finally, Strategic Blueprint LLC lifted its stake in Vertex Pharmaceuticals by 1.7% during the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock valued at $726,000 after acquiring an additional 25 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.0%

NASDAQ:VRTX opened at $383.12 on Friday. The stock has a market cap of $98.23 billion, a P/E ratio of 27.39 and a beta of 0.44. The stock has a 50 day simple moving average of $414.44 and a 200 day simple moving average of $450.38. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. BMO Capital Markets set a $530.00 price target on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a research report on Tuesday, August 5th. Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Evercore ISI lowered their price objective on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. Finally, Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $496.05.

Insider Activity

In other news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.